Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children.

Viisanen T, Gazali AM, Ihantola EL, Ekman I, Näntö-Salonen K, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T.

Front Immunol. 2019 Jan 22;10:19. doi: 10.3389/fimmu.2019.00019. eCollection 2019.

2.

Abnormal coagulation and enhanced fibrinolysis due to lysinuric protein intolerance associates with bleeds and renal impairment.

Pitkänen HH, Kärki M, Niinikoski H, Tanner L, Näntö-Salonen K, Pikta M, Kopatz WF, Zuurveld M, Meijers JCM, Brinkman HJM, Lassila R.

Haemophilia. 2018 Sep;24(5):e312-e321. doi: 10.1111/hae.13543. Epub 2018 Aug 2.

PMID:
30070418
3.

Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes.

Ihantola EL, Viisanen T, Gazali AM, Näntö-Salonen K, Juutilainen A, Moilanen L, Rintamäki R, Pihlajamäki J, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T.

J Immunol. 2018 Aug 15;201(4):1144-1153. doi: 10.4049/jimmunol.1701199. Epub 2018 Jul 13.

PMID:
30006377
4.

Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies.

Viisanen T, Ihantola EL, Näntö-Salonen K, Hyöty H, Nurminen N, Selvenius J, Juutilainen A, Moilanen L, Pihlajamäki J, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T.

Diabetes. 2017 Feb;66(2):437-447. doi: 10.2337/db16-0714. Epub 2016 Oct 10.

5.

Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance.

Tanner LM, Kurko J, Tringham M, Aho H, Mykkänen J, Näntö-Salonen K, Niinikoski H, Lukkarinen H.

JIMD Rep. 2017;34:97-104. doi: 10.1007/8904_2016_15. Epub 2016 Oct 26.

6.

Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI).

Kurko J, Tringham M, Tanner L, Näntö-Salonen K, Vähä-Mäkilä M, Nygren H, Pöhö P, Lietzen N, Mattila I, Olkku A, Hyötyläinen T, Orešič M, Simell O, Niinikoski H, Mykkänen J.

Metabolism. 2016 Sep;65(9):1361-75. doi: 10.1016/j.metabol.2016.05.012. Epub 2016 May 27.

PMID:
27506743
7.

Clinical, Genetic, and Biochemical Characteristics of Early-Onset Diabetes in the Finnish Population.

Huopio H, Miettinen PJ, Ilonen J, Nykänen P, Veijola R, Keskinen P, Näntö-Salonen K, Vangipurapu J, Raivo J, Stančáková A, Männistö J, Kuulasmaa T, Knip M, Otonkoski T, Laakso M.

J Clin Endocrinol Metab. 2016 Aug;101(8):3018-26. doi: 10.1210/jc.2015-4296. Epub 2016 May 11.

PMID:
27167055
8.

Dysfunction in macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport.

Kurko J, Vähä-Mäkilä M, Tringham M, Tanner L, Paavanen-Huhtala S, Saarinen M, Näntö-Salonen K, Simell O, Niinikoski H, Mykkänen J.

Mol Immunol. 2015 Oct;67(2 Pt B):416-25. doi: 10.1016/j.molimm.2015.07.006. Epub 2015 Jul 22.

PMID:
26210182
9.

Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI.

Kärki M, Näntö-Salonen K, Niinikoski H, Tanner LM.

JIMD Rep. 2016;25:47-55. Epub 2015 Jun 30.

10.

Virus infections among young children--the first year of the INDIS study.

Simonen-Tikka ML, Klemola P, Suomenrinne S, Kaijalainen S, Söderström D, Savolainen-Kopra C, Näntö-Salonen K, Ilonen J, Simell T, Simell O, Roivainen M.

J Med Virol. 2013 Sep;85(9):1678-84. doi: 10.1002/jmv.23625. Epub 2013 Jun 21.

PMID:
23794481
11.

Human rhinoviruses in INDIS-study material-evidence for recovery of viable rhinovirus from fecal specimens.

Savolainen-Kopra C, Simonen-Tikka ML, Klemola P, Blomqvist S, Suomenrinne S, Näntö-Salonen K, Simell O, Roivainen M.

J Med Virol. 2013 Aug;85(8):1466-72. doi: 10.1002/jmv.23593.

PMID:
23765783
12.

[Is it necessary to monitor the cognitive development of a child having diabetes?].

Näntö-Salonen K, Hannonen R.

Duodecim. 2012;128(8):802-9. Review. Finnish.

PMID:
22616371
13.

Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.

Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O.

Diabetologia. 2012 Jul;55(7):1926-36. doi: 10.1007/s00125-012-2523-3. Epub 2012 Mar 23.

PMID:
22441569
14.

Exploring the transcriptomic variation caused by the Finnish founder mutation of lysinuric protein intolerance (LPI).

Tringham M, Kurko J, Tanner L, Tuikkala J, Nevalainen OS, Niinikoski H, Näntö-Salonen K, Hietala M, Simell O, Mykkänen J.

Mol Genet Metab. 2012 Mar;105(3):408-15. doi: 10.1016/j.ymgme.2011.12.007. Epub 2011 Dec 16.

PMID:
22221392
15.

Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes.

Ryhänen SJ, Härkönen T, Siljander H, Näntö-Salonen K, Simell T, Hyöty H, Ilonen J, Veijola R, Simell O, Knip M.

Diabetes Care. 2011 Jun;34(6):1383-8. doi: 10.2337/dc10-1449. Epub 2011 Apr 22.

16.

Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Niinikoski H, Lapatto R, Nuutinen M, Tanner L, Simell O, Näntö-Salonen K.

JIMD Rep. 2011;1:43-7. doi: 10.1007/8904_2011_15. Epub 2011 Jun 22.

17.

19p13.3 aberrations are associated with dysmorphic features and deviant psychomotor development.

Siggberg L, Olsén P, Näntö-Salonen K, Knuutila S.

Cytogenet Genome Res. 2011;132(1-2):8-15. doi: 10.1159/000320920. Epub 2010 Oct 8.

PMID:
20938164
18.

[Insulin-induced lipoatrophy in children].

Niinikoski H, Näntö-Salonen K, Ruusu P, Kinnala A, Putto-Laurila A, Toppari J, Keskinen P.

Duodecim. 2010;126(11):1328-32. Finnish.

PMID:
20681357
19.

Combined hyperlipidemia in patients with lysinuric protein intolerance.

Tanner LM, Niinikoski H, Näntö-Salonen K, Simell O.

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S145-50. doi: 10.1007/s10545-010-9050-5. Epub 2010 Feb 23.

PMID:
20177788
20.

From genetic risk awareness to overt type 1 diabetes: parental stress in a placebo-controlled prevention trial.

Goldstein E, Hermann R, Renfors TJ, Näntö-Salonen KM, Korhonen T, Kärkkäinen M, Veijola RK, Knip M, Simell TT, Simell OG.

Diabetes Care. 2009 Dec;32(12):2181-3. doi: 10.2337/dc09-0423. Epub 2009 Sep 14.

21.

[Phenylketonuria].

Niinikoski H, Heikkilä J, Näntö-Salonen K.

Duodecim. 2009;125(10):1069-75. Finnish.

PMID:
19585905
22.

Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes.

Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O.

J Exp Med. 2008 Dec 22;205(13):2975-84. doi: 10.1084/jem.20081800. Epub 2008 Dec 15.

23.

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O.

Lancet. 2008 Nov 15;372(9651):1746-55. doi: 10.1016/S0140-6736(08)61309-4. Epub 2008 Sep 22.

PMID:
18814906
24.

Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Rashed MS, Kotilainen S, Aalto M, Venetoklis J, Niinikoski H, Huoponen K, Simell O.

Metabolism. 2008 Apr;57(4):549-54. doi: 10.1016/j.metabol.2007.11.019.

PMID:
18328359
25.

Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study.

Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, Raitakari OT, Jula A, Marniemi J, Näntö-Salonen K, Simell O.

Circulation. 2007 Aug 28;116(9):1032-40. Epub 2007 Aug 13.

PMID:
17698729
26.

Nutrient intake in lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Venetoklis J, Kotilainen S, Niinikoski H, Huoponen K, Simell O.

J Inherit Metab Dis. 2007 Oct;30(5):716-21. Epub 2007 Jun 21.

PMID:
17588131
27.

Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Niinikoski H, Jahnukainen T, Keskinen P, Saha H, Kananen K, Helanterä A, Metso M, Linnanvuo M, Huoponen K, Simell O.

J Pediatr. 2007 Jun;150(6):631-4, 634.e1.

PMID:
17517249
28.

Long-term oral lysine supplementation in lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Niinikoski H, Huoponen K, Simell O.

Metabolism. 2007 Feb;56(2):185-9.

PMID:
17224331
29.

The diagnosis of ectopic focal hyperinsulinism of infancy with [18F]-dopa positron emission tomography.

Hussain K, Seppänen M, Näntö-Salonen K, Adzick NS, Stanley CA, Thornton P, Minn H.

J Clin Endocrinol Metab. 2006 Aug;91(8):2839-42. Epub 2006 May 9.

PMID:
16684819
30.

Poor cognitive development and abdominal pain: Wilson's disease.

Grönlund J, Näntö-Salonen K, Venetoklis J, Holmberg RL, Heinonen A, Ståhlberg MR.

Scand J Gastroenterol. 2006 Mar;41(3):361-4.

PMID:
16497628
31.

Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study.

Hakanen M, Lagström H, Kaitosaari T, Niinikoski H, Näntö-Salonen K, Jokinen E, Sillanmäki L, Viikari J, Rönnemaa T, Simell O.

Int J Obes (Lond). 2006 Apr;30(4):618-26.

PMID:
16446743
32.

Hazards associated with pregnancies and deliveries in lysinuric protein intolerance.

Tanner L, Näntö-Salonen K, Niinikoski H, Erkkola R, Huoponen K, Simell O.

Metabolism. 2006 Feb;55(2):224-31.

PMID:
16423630
33.

Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography.

Otonkoski T, Näntö-Salonen K, Seppänen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekström K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H.

Diabetes. 2006 Jan;55(1):13-8.

34.

Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.

Autti-Rämö I, Mäkelä M, Sintonen H, Koskinen H, Laajalahti L, Halila R, Kääriäinen H, Lapatto R, Näntö-Salonen K, Pulkki K, Renlund M, Salo M, Tyni T.

Acta Paediatr. 2005 Aug;94(8):1126-36.

PMID:
16188860
35.

Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment.

Hero M, Jänne OA, Näntö-Salonen K, Dunkel L, Raivio T.

J Clin Endocrinol Metab. 2005 Sep;90(9):5141-5. Epub 2005 Jun 28.

PMID:
15985486
36.

Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.

Cuesta-Muñoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Näntö-Salonen K, Rahier J, López-Enriquez S, García-Gimeno MA, Sanz P, Soriguer FC, Laakso M.

Diabetes. 2004 Aug;53(8):2164-8.

37.

Epitopes recognized by CBV4 responding T cells: effect of type 1 diabetes and associated HLA-DR-DQ haplotypes.

Marttila J, Hyöty H, Näntö-Salonen K, Simell O, Ilonen J.

Virology. 2004 Feb 5;319(1):27-35.

38.

Oral supplementation corrects plasma lysine concentrations in lysinuric protein intolerance.

Lukkarinen M, Näntö-Salonen K, Pulkki K, Aalto M, Simell O.

Metabolism. 2003 Jul;52(7):935-8.

PMID:
12870174
39.

Peripheral nervous system in gyrate atrophy of the choroid and retina with hyperornithinemia.

Peltola KE, Jääskeläinen S, Heinonen OJ, Falck B, Näntö-Salonen K, Heinänen K, Simell O.

Neurology. 2002 Sep 10;59(5):735-40.

PMID:
12221166
40.

[The mystery of a red buttock].

Nänto-Salonen K.

Duodecim. 1999;115(6):681,683. Finnish. No abstract available.

PMID:
11892613
41.

Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children.

Järvisalo MJ, Jartti L, Näntö-Salonen K, Irjala K, Rönnemaa T, Hartiala JJ, Celermajer DS, Raitakari OT.

Circulation. 2001 Dec 11;104(24):2943-7.

PMID:
11739310
42.

Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase.

Peltola KE, Näntö-Salonen K, Heinonen OJ, Jääskeläinen S, Heinänen K, Simell O, Nikoskelainen E.

Ophthalmology. 2001 Apr;108(4):721-9.

PMID:
11297489
43.

Oral lysine feeding in gyrate atrophy with hyperornithinaemia--a pilot study.

Peltola K, Heinonen OJ, Näntö-Salonen K, Pulkki K, Simell O.

J Inherit Metab Dis. 2000 Jun;23(4):305-7. No abstract available.

PMID:
10896280
44.

Effect of lysine infusion on urea cycle in lysinuric protein intolerance.

Lukkarinen M, Näntö-Salonen K, Pulkki K, Mattila K, Simell O.

Metabolism. 2000 May;49(5):621-5.

PMID:
10831173
45.

Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets.

Tyynismaa H, Kaitila I, Näntö-Salonen K, Ala-Houhala M, Alitalo T.

Hum Mutat. 2000 Apr;15(4):383-4.

PMID:
10737991
46.

Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.

Valtonen M, Näntö-Salonen K, Jääskeläinen S, Heinänen K, Alanen A, Heinonen OJ, Lundbom N, Erkintalo M, Simell O.

J Inherit Metab Dis. 1999 Dec;22(8):855-66.

PMID:
10604138
47.

Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia.

Heinänen K, Näntö-Salonen K, Komu M, Erkintalo M, Alanen A, Heinonen OJ, Pulkki K, Nikoskelainen E, Sipilä I, Simell O.

Eur J Clin Invest. 1999 Dec;29(12):1060-5.

PMID:
10583455
48.

Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia.

Nänto-Salonen K, Komu M, Lundbom N, Heinänen K, Alanen A, Sipilä I, Simell O.

Neurology. 1999 Jul 22;53(2):303-7.

PMID:
10430418
49.

Serum type III procollagen in children with type I hereditary tyrosinemia.

Pitkänen S, Salo MK, Vettenranta K, Näntö-Salonen K, Heikinheimo M.

J Pediatr Gastroenterol Nutr. 1999 Jul;29(1):38-41.

PMID:
10400101
50.

Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia--clues to pathogenesis.

Heinänen K, Näntö-Salonen K, Komu M, Erkintalo M, Heinonen OJ, Pulkki K, Valtonen M, Nikoskelainen E, Alanen A, Simell O.

Eur J Clin Invest. 1999 May;29(5):426-31.

PMID:
10354199

Supplemental Content

Loading ...
Support Center